Literature DB >> 7531513

An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age.

Y C Chang1, K D Smith, R D Moore, G R Serjeant, G J Dover.   

Abstract

Five factors have been shown to influence the 20-fold variation of fetal hemoglobin (Hb F) levels in sickle cell anemia (SS): age, sex, the alpha-globin gene number, beta-globin haplotypes, and an X-linked locus that regulates the production of Hb F-containing erythrocytes (F cells), ie, the F-cell production (FCP) locus. To determine the relative importance of these factors, we studied 257 Jamaican SS subjects from a Cohort group identified by newborn screening and from a Sib Pair study. Linear regression analyses showed that each variable, when analyzed alone, had a significant association with Hb F levels (P < .05). Multiple regression analysis, including all variables, showed that the FCP locus is the strongest predictor, accounting for 40% of Hb F variation. beta-Globin haplotypes, alpha-globin genes, and age accounted for less than 10% of the variation. The association between the beta-globin haplotypes and Hb F levels becomes apparent if the influence of the FCP locus is removed by analyzing only individuals with the same FCP phenotype. Thus, the FCP locus is the most important factor identified to date in determining Hb F levels. The variation within each FCP phenotype is modulated by factors associated with the three common beta-globin haplotypes and other as yet unidentified factor(s).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531513

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Authors:  Susan P Perrine; William A Wargin; Michael S Boosalis; Wayne J Wallis; Sally Case; Jeffrey R Keefer; Douglas V Faller; William C Welch; Ronald J Berenson
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

Review 2.  Fetal hemoglobin in sickle cell anemia.

Authors:  Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

3.  Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster.

Authors:  Nadia Solovieff; Jacqueline N Milton; Stephen W Hartley; Richard Sherva; Paola Sebastiani; Daniel A Dworkis; Elizabeth S Klings; Lindsay A Farrer; Melanie E Garrett; Allison Ashley-Koch; Marilyn J Telen; Supan Fucharoen; Shau Yin Ha; Chi-Kong Li; David H K Chui; Clinton T Baldwin; Martin H Steinberg
Journal:  Blood       Date:  2009-12-16       Impact factor: 22.113

Review 4.  Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.

Authors:  Alawi H Habara; Elmutaz M Shaikho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

Review 5.  Fetal haemoglobin induction in sickle cell disease.

Authors:  Alireza Paikari; Vivien A Sheehan
Journal:  Br J Haematol       Date:  2017-11-16       Impact factor: 6.998

6.  Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study.

Authors:  Kabir O Olaniran; Andrew S Allegretti; Sophia H Zhao; Maureen M Achebe; Nwamaka D Eneanya; Ravi I Thadhani; Sagar U Nigwekar; Sahir Kalim
Journal:  J Am Soc Nephrol       Date:  2019-12-06       Impact factor: 10.121

Review 7.  Carrier screening and genetic counselling in beta-thalassemia.

Authors:  Antonio Cao
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.

Authors:  Françoise Bernaudin; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Françoise Lelong; Ralph Epaud; Corinne Pondarré; Serge Pissard
Journal:  Blood Adv       Date:  2018-03-27

9.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30

10.  A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth Ataga; Marvin Reid; Elliott P Vichinsky; Lynne Neumayr; Loray Blair-Britt; Richard Labotka; Jonathan Glass; Jeffrey R Keefer; William A Wargin; Ronald Berenson; Susan P Perrine
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.